Table 1.
Response rate and tumor cell characteristics of ABC treated with bevacizumab plus nab-paclitaxel52,53
| Response | ||||||
|---|---|---|---|---|---|---|
| Total patients | CR (n) | ORR (%) | SD (n) | CB (%) | PD | |
| Er-pos or PgR-pos | 23 | 1 | 43.5% | 4 | 60.9% | 9 |
| Er-neg or PgR-neg | 10 | 2 | 60% | 1 | 70% | 3 |
| Her-2-neg | 21 | 2 | 47.6% | 1 | 52.4% | 10 |
| Her-2-pos | 12 | 1 | 50.% | 4 | 83.3% | 2 |
| Triple neg | 4 | 1 | 75% | 0 | 75% | 1 |
| Total | 33 | 3 | 48.5% | 5 | 63.9% | 12 |
Abbreviations: CR, complete response; ORR, overall response rate; PD, progressive disease; SD, stable disease; PgR, progesterone receptor; ER, estrogen receptor; CB, clinical benefit.